
A SIGNAL TO NOISE RATIO CLASSIFICATION SYSTEM OF DRUGS TO INVESTIGATE GENERIC DRUG INEFFECTIVENESS CLAIMS


How to address the complaints of loss of efficacy for generic drugs?

Eliford N. Kitabi


Email: ekitabi@rx.umaryland.edu

Funded by FDA grant no: 1U01FD005192-01


Key decisions




Devising the classification system



Estimated typical RR vs assigned Priority bins



Decision tree to classify drugs into priority bins



Acknowledgments

- Research Team
 - Mathangi Gopalakrishnan, Vijay Ivaturi, Gobburu Joga
- CTM partners
 - Elyes Dahmane, Shailly Mehrotra, Tao Liu, Devin Pastoor, Jing Niu, Shamir Kalaria, Hechuan Wang, Neha Mehta, James Derby
- The University of Maryland Baltimore

1. This research was funded by FDA grant number 1U01FD005192-01
2. The research team has nothing further to disclose

Post-activity Questions

1. The following may not be the reason for the loss of treatment efficacy when patient switch from brand to generic drug treatment.
 - a. Bad perception about generic drug effectiveness
 - b. Pharmacokinetic interaction with foods commonly taken by the patient
 - c. Less drug exposure from generic compared brand drug
2. One of the suggested approach to address the complaints of loss of efficacy is:
 - a. Perform laboratory and clinical investigation to compare drug exposure between generic and brand drug formulations for all drugs with complaints.
 - b. Prioritize the investigations to drugs with good discrimination between active drug treatment effect and placebo treatment effect.
 - c. Never to investigate those complaints at all since the generic drugs have already passed the therapeutic equivalence test compared to brand drugs.